COMPANY

Skye Bioscience

HQ: San Diego, CA source · skyebioscience.com ↗ · West Coast

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Keywords: Primary Open Angle Glaucoma Ocular Hypertension Obesity SBI-100

Timeline

Aug 22, 2024 Trial start Phase 2: Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo source ↗
Nov 9, 2023 Trial start Phase 2: Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure source ↗

Nov 20, 2026 (ESTIMATED) · Phase 2 · Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo · NCT06577090

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT06144918	Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure	Phase 2	Completed	Nov 9, 2023	Feb 22, 2024 (actual)
NCT06577090	Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo	Phase 2	Active, not recruiting	Aug 22, 2024	Nov 20, 2026 (estimated)